---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-013984"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T15:28:54.295003+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals

## Summary
- Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).
- GAAP net income $181.739M ($0.82 diluted EPS) vs net loss $15.203M in Q3 2020.
- Non-GAAP net income $261.824M ($1.18 diluted EPS) vs $50.059M.
- FDA approved Opzelura for atopic dermatitis, Jakafi for chronic GVHD; Minjuvi OK'd in EU.
- Reaffirmed FY2021 guidance: Jakafi net product rev $2,125-$2,170M; R&D $1,350-$1,390M GAAP.

## SEC filing metadata
- accession: 0001558370-21-013984
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000155837021013984/0001558370-21-013984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000155837021013984/incy-20211102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-013984
- JSON: https://secwatch.observer/filing/0001558370-21-013984.json
- Plain text: https://secwatch.observer/filing/0001558370-21-013984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.